India Plans Price Controls on Patented Drugs - WSJ.com - 0 views
-
Stella Nuber on 05 Nov 12India is looking to expand the price controls they have on drugs. This would apply not only to generic medicines, but also to patented drugs. Drug companies fear this decision, as they feel that India is not protecting their intellectual property enough already. The secretary of India's Pharmaceuticals Department, Kalha, states that they need to make expensive drugs available/affordable to the poorer citizens. Bayer AG and India are in a patent conflict. India's patent authority required that the German company, Bayer, issues a license, which allows Indian generic- drug companies to sell a less expensive copy of Bayer's patented cancer drug, Nexavar. The reason for this order was due to the expensive prices of the drug and India's Intellectual Property Appellate Board are arguing the case and expecting a ruling very soon. With the price controls on the drugs, the poorer citizens would have a fairer chance and curing their sicknesses, as they would be able to afford the medication for it. So far India has 74 set prices on generic medicines but is wanting to increase this number to 348. This high amount of price control has not been seen since 1979! The Indian government believes that the prices of drugs shouldn't be driven by market forces but should be regulated instead. However, so far there are no formal regulations to the plan of the price controlling yet, as the government is still deciding of final opinions. By restricting the prices of drugs, foreign pharmaceutical companies might become upset. Tapan Ray, the director general of the Organization of Pharmaceutical Producers (internationally based) of India spoke: " any price control in that area will stifle [research and development] initiatives seriously, adversely affecting patients' interests in the long run". Novartis is a Swiss drug maker and it has been fighting for a patent on its cancer drug, Glivec, in India. In 2006 India rejected Novartis' patent application, and since then Novartis has been fighting